Related Experiment Videos
Impact of comorbidities on D-dimer and CRP in covid-19 patients: A comparative retrospective analysis
Jyoti Shukla1, Ritesh Yadav2, Girish Dubey2
1Department of Biochemistry, Shrimant Rajmata Vijayaraje Scindia Medical College, Shivpuri, Madhya Pradesh, India.
Insights
Higher inflammatory markers like C-reactive protein (CRP) and D-dimer were observed in multimorbid COVID-19 patients. Monitoring these biomarkers is crucial for managing patients with comorbidities.
Area of Science:
- Medical Research
- Infectious Diseases
- Clinical Medicine
Background:
- The COVID-19 pandemic highlighted the importance of inflammatory biomarkers for prognosis.
- Understanding the impact of comorbidities on these markers is vital for patient management.
Purpose of the Study:
- To investigate the correlation between comorbidity burden and inflammatory markers (CRP and D-dimer) in hospitalized COVID-19 patients.
- To assess differences in CRP and D-dimer levels across non-comorbid, comorbid, and multimorbid patient groups.
Main Methods:
- Analysis of 100 hospitalized COVID-19 patients at a tertiary care center.
- Categorization of patients based on comorbidity status: non-comorbid, comorbid, and multimorbid.
- Measurement and comparison of C-reactive protein (CRP) and D-dimer levels among the groups.
Main Results:
- Multimorbid COVID-19 patients exhibited significantly higher levels of both D-dimer and CRP compared to comorbid and non-comorbid groups (p<0.05).
- The study included a mean age of 53.18 ± 15.48 years with a male predominance (63%).
Conclusions:
- Elevated inflammatory biomarkers (CRP and D-dimer) are associated with increased comorbidity burden in COVID-19 patients.
- Monitoring these biomarkers aids in early identification of disease progression and guides targeted therapeutic interventions in patients with comorbidities.
Abstract:
The coronavirus disease 2019 (COVID-19) pandemic has posed significant challenges to healthcare systems, with inflammatory biomarkers emerging as important prognostic indicators. Therefore, it is of interest to evaluate the correlation between comorbidity burden and inflammatory markers-C-reactive protein (CRP) and D-dimer-in 100 hospitalized COVID-19 patients at a tertiary care center in Madhya Pradesh, India. Patients were categorized as non-comorbid (n=31), comorbid (n=30) and multimorbid (n=39), with a mean age of 53.18 ± 15.48 years and male predominance (63%). D-dimer and CRP levels were significantly higher in multimorbid patients compared to comorbid and non-comorbid groups (p<0.05). Thus, we show the importance of monitoring inflammatory biomarkers in COVID-19 patients with comorbidities for early identification of disease progression and targeted therapeutic intervention.
Related Concept Videos
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin create...
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Acute Coronary Syndrome III: Diagnostic Studies
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...